Baricitinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CONITEC (Brazil) and ZIN (Netherlands) recommended or restricted baricitinib, while CIPM (Spain) did not recommend it.
NYE METODER (Norway) has been harder on baricitinib than on its own caseload: it refused 3 of 5 decisive submissions here (60%), against a base rate of 37% across everything it has assessed.
Assessment has run over 9 years, from 3 Feb 2017 at AWMSG (Wales) to 18 Feb 2026 at HAS (France).
PBAC (Australia) changed its position: recommended in 2018, not recommended by 2021.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for baricitinib, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 22 of 48 records date from 2023 or later.
The programme is broad: 11 distinct indication wordings are recorded for baricitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 48 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess baricitinib, on 3 Feb 2017; ZIN (Netherlands) did not open a file until 31 Jul 2024 — a wide spread of 7.4 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 9 years in total.
12 of the 14 agencies here assessed baricitinib more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
baricitinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for baricitinib reads 15 recommended, 11 not recommended, 8 restricted and 7 no benefit, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 17 Dec 2025 | Indication extension | SMR low · ASMR V | source |
| NYE METODER (Norway) | 27 Apr 2025 | Behandling av alvorlig flekkvist håravfall (alopecia areata) | not introduced | source |
| ZIN (Netherlands) | 31 Jul 2024 | Advies - vergoed baricitinib (Olumiant®) voor de behandeling van ernstige alopecia areata | reimbursed | source |
| NICE (England) | 13 Jun 2024 | NICE TA982 | terminated appraisal | source |
| AWMSG (Wales) | 13 Jun 2024 | for treating juvenile idiopathic arthritis in people 2 years and over | outside AWMSG criteria | source |
43 further decisions for baricitinib, across 13 agencies, are not shown here. They include the most recent record on file, 18 Feb 2026 from HAS (France); its outcome is in the subscriber dataset. They link to 33 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 48 decisions for baricitinib from 14 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.